Richter's Transformation clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Sorry, in progress, not accepting new patients
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.
Los Angeles, California and other locations
Our lead scientists for Richter's Transformation research studies include Herbert Eradat.
Last updated: